Pascal Neuville

Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France.

Peptimimesis SAS provides biotechnology research services. Its platform delivers a set of drug candidates that act on strategic targets in the field of immuno-oncology, oncology, and immune diseases. The company was founded by Dominique Bagnard and Pascal Neuville in October 2015 and is headquartered in Strasbourg, France.

Find Therapeutics develops therapeutics for inflammatory and fibrotic disease. The company is headquartered in Saint-Laurent, Canada.

Mavalon Therapeutics Ltd. develops orally available small molecule able to induce glial cell line-derived neurotropic factor production within the brain of parkinson’s patients. The company is headquartered in Hatfield, the United Kingdom.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Alsace BioValley Association operates as a health innovation center. The private company is based in Illkirch, France.